Avanafil for male erectile dysfunction: a systematic review and meta-analysis

Area of Science:

• Pharmacology
• Urology
• Clinical Trials

Background:

• Erectile dysfunction (ED) is a common condition affecting many men.
• Phosphodiesterase type 5 (PDE5) inhibitors are a primary treatment for ED.
• Avanafil is a novel, selective PDE5 inhibitor developed for ED treatment.

Purpose of the Study:

• To systematically review and meta-analyze the efficacy and safety of avanafil for ED treatment.
• To assess avanafil's effectiveness in improving sexual activity outcomes.
• To evaluate the safety profile and adverse events associated with avanafil therapy.

Main Methods:

• Systematic review and meta-analysis of published randomized, double-blind, placebo-controlled trials.
• Literature search conducted across MEDLINE, EMBASE, and Cochrane Controlled Trials Register.
• Analysis included four trials with a total of 1381 patients comparing avanafil to placebo.

Main Results:

• Avanafil (100 mg) significantly improved successful vaginal penetration (SEP2) and intercourse (SEP3) compared to placebo (OR=5.06, P<0.00001 and OR=3.99, P<0.00001, respectively).
• Patients receiving avanafil were not significantly more likely to discontinue treatment due to adverse events (OR=1.48, P=0.44).
• Headache and flushing were reported adverse events, but less frequent with avanafil than placebo; higher doses (200 mg) increased headache likelihood.

Conclusions:

• Avanafil (100 or 200 mg) is an effective and well-tolerated treatment for erectile dysfunction.
• The drug demonstrates significant improvements in key efficacy endpoints for ED.
• While generally safe, dose-dependent side effects like headaches warrant consideration.